IMAB Market Capitalization from 2010 to 2024
| IMAB Stock | USD 0.93 0.02 2.11% |
Check I Mab financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among I Mab's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 53.6 M or Interest Income of 54.3 M, as well as many indicators such as Price To Sales Ratio of 38.23, Dividend Yield of 0.0151 or PTB Ratio of 1.04. IMAB financial statements analysis is a perfect complement when working with I Mab Valuation or Volatility modules.
IMAB | Market Capitalization |
Latest I Mab's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of I Mab over the last few years. It is I Mab's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in I Mab's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 85.74 M | 10 Years Trend |
|
Market Cap |
| Timeline |
IMAB Market Capitalization Regression Statistics
| Arithmetic Mean | 3,371,278,962 | |
| Geometric Mean | 578,051,498 | |
| Coefficient Of Variation | 224.42 | |
| Mean Deviation | 4,948,314,081 | |
| Median | 203,059,559 | |
| Standard Deviation | 7,565,886,301 | |
| Sample Variance | 57242635.5T | |
| Range | 22.7B | |
| R-Value | 0.37 | |
| Mean Square Error | 53172178T | |
| R-Squared | 0.14 | |
| Significance | 0.17 | |
| Slope | 627,234,814 | |
| Total Sum of Squares | 801396897.3T |
IMAB Market Capitalization History
About I Mab Financial Statements
I Mab stakeholders use historical fundamental indicators, such as I Mab's Market Capitalization, to determine how well the company is positioned to perform in the future. Although I Mab investors may analyze each financial statement separately, they are all interrelated. For example, changes in I Mab's assets and liabilities are reflected in the revenues and expenses on I Mab's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in I Mab. Please read more on our technical analysis and fundamental analysis pages.
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. The company was founded in 2014 and is headquartered in Shanghai, the Peoples Republic of China. I-Mab ADR operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 378 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether I Mab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of I Mab's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of I Mab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on I Mab Stock:Check out the analysis of I Mab Correlation against competitors. For information on how to trade IMAB Stock refer to our How to Trade IMAB Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of I Mab. If investors know IMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about I Mab listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.16) | Revenue Per Share 0.043 | Quarterly Revenue Growth (0.62) | Return On Assets (0.29) | Return On Equity (0.72) |
The market value of I Mab is measured differently than its book value, which is the value of IMAB that is recorded on the company's balance sheet. Investors also form their own opinion of I Mab's value that differs from its market value or its book value, called intrinsic value, which is I Mab's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because I Mab's market value can be influenced by many factors that don't directly affect I Mab's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between I Mab's value and its price as these two are different measures arrived at by different means. Investors typically determine if I Mab is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, I Mab's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.